Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.

doi:10.1016/j.lungcan.2005.07.012

Article

Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.

Lung cancer (Amsterdam, Netherlands) - 1 Dec 2005

Kimura Hideharu, Kasahara Kazuo, Sekijima Masaru, Tamura Tomohide, Nishio Kazuto

Abstract excerpt

Gefitinib (Iressa() is an orally active, selective EGFR tyrosine kinase inhibitor that blocks signal transduction pathways. Skin toxicity has been reported to be the major toxicity observed in patients treated with the EGFR-targeted tyrosine kinase inhibitors, such as gefitinib and erlotinib. Although the mechanisms underlying the development of the skin toxicity remain to be precisely clarified, immunological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.

Abstract excerpt

Topics

Related research